CancerFACE-TC-SpNCT04095000
Health Equity: Advance Care Planning for Spanish Speaking Teens With Cancer-1st Resubmission
A study testing FACE-TC SP and Treatment as Usual in people with Cancer, run by Maureen Lyon at 1 site in United States.
Trial summary
Pediatric ACP (Advance Care Planning) (pACP) (1) Supports communication with children/adolescents at any stage of a serious illness in understanding their illness, complications, fears, and hopes, as well as treatment preferences regarding future medical care with their family; (2) Communicates these goals of care and… Read more about this study
- Who is it for?
- Ages 14 to 99 years
- Conditions the study is for
- Cancer
- What is being tested?
- FACE-TC SP and Treatment as Usual
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Sep 2019to 5 Aug 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 99 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Adolescent Inclusion Criteria:
- ≥14.0 years and <21.0 years at the time of enrollment
- primary language is Spanish
Surrogate Inclusion Criteria:
- >17 years
Exclusion Criteria for adolescents and surrogate decision makers/legal guardians:
- currently experiencing symptoms of depression in the severe range, homicidality, suicidality or psychosis at secondary screening
- known to be developmentally delayed
Trial locations and contacts
1 site in 1 country.
United States1 site
Children's National Medical Center
Washington D.C., District of Columbia, 22314
About this study
Pediatric ACP (Advance Care Planning) (pACP) (1) Supports communication with children/adolescents at any stage of a serious illness in understanding their illness, complications, fears, and hopes, as well as treatment preferences regarding future medical care with their family; (2) Communicates these goals of care and treatment preferences with their physician; and (3) Documents these goals of care and end-of-life treatment preferences. Among adolescents, cancer is the leading cause of disease-related deaths. Survival has improved far less for 15 to 24 year-olds than it has for older patients. About one-fourth will die prematurely. No pediatric Advance Care Planning (pACP) model exists to serve Spanish speaking adolescents with cancer.
Objective: To take first steps to implement pACP as a routine, structured intervention in pediatric hospitals with underserved Spanish speaking adolescents living with cancer through timely conversations with their families to relieve suffering (physical, psychological, spiritual) and maximize the quality of life
Read the detailed description
Non-English-speaking patients are far less likely to have advance care planning documents than English speakers. Some ethnicities in an adult study had no patients with an advance care planning document. Since completing advance care planning may increase early palliative care enrollment, as it did in the FACE-TC study, strategies to promote pACP are urgently needed, particularly with non-English speaking patients.
Transactional stress and coping theory is the basis for the FACE intervention, because interventions can change the appraisal of an illness from that of a death threat to a challenge with potential for personal growth and mastery.
Many adolescents want to talk about their goals and values regarding their own end-of-life care. These important discussions are often regarded as needed, but not initiated before a medical crisis, due to perceived (and unwarranted) fears they will cause anxiety, take away hope or cause physician or family discomfort. Parents who discussed death with their children who were dying of cancer reported no regrets. Pediatric ACP for adolescent cancer patients is a public health issue, because of its high burden and potential for the prevention of suffering, as most teen and young adult cancer patients at end of life get aggressive care. The proposed study will explore prospectively whether Hispanic/Latino teens can be safely supported to help them make informed choices with their families, advancing clinical practice. Heretofore, family refers to the legal guardian(s) or surrogate decision maker(s) of the adolescent patient with cancer.
Age appropriate communication that includes the adolescent and family can facilitate decisions about medical treatments that precede death. Competency to participate in decision-making has been challenged by research on adolescent brain development, which demonstrates the structure of the adolescent brain is not fully formed.
However, what these findings mean in terms of the actual functioning or behavior of an individual adolescent is unclear, stirring up legal and public policy debates. The implications for pACP are unclear. Empirical evidence and the ethical principles of justice and autonomy support the practice of including adolescents in decision-making about their future medical care, if they could not speak for themselves. Cognitive capacities required for "informed consent" for medical treatment exist in early adolescence. Nor is there reason to suspect that young adolescents have a less mature understanding of death: irreversibility; finality or non-functionality; universality or inevitability; and causality. Hinds and colleagues found that children with cancer realized they were involved in an end-of-life decision, understood the consequences of their decision (that death is the outcome no matter what), and could share the reasons for their preferences. The decision factors most frequently reported by pediatric patients were relationship based, while parents identified good communication. Parents also thought that communicating with the child about end-of-life preferences was appropriate when approached with sensitivity and care. The issues facing adolescents with a life-threatening illness are different from those facing adults, because minors' preferences are not legally binding.
Culture and ethnicity are important in pACP. Cultural values differ with respect to patient autonomy. For those adolescents who do not want to defer these decisions to their family or physician, culturally sensitive pACP conversations may ensure patients and families feel cared for and supported, when there is full participation by the family and clear communication to the physician. Hospice surveys show one-third of Latinos opposed life support that prolonged suffering, leading the National Hospice and Palliative Care Organization to actively reach out to Latino communities. Immigrant status influences decisions about aggressive treatments, suggesting there may not be disparities in EOL care, but rather differences in preferences. Investigators will explore whether the number of years residing in the U.S. influences treatment choices among study participants.
The FACE intervention is informed by the American Academy of Pediatrics, the Institute of Medicine (IOM), institutional guidelines, and evolving practice and theory recommending: (1) that decisions about end-of-life (EOL) care be shared among the adolescent patient, family, and physician; (2) that these discussions take place when the patient is stable; (3) and that decisions be individualized. In the SUPPORT study physicians misunderstood the patient's preferences about CPR in 80% of the cases. Clinical reports suggest that parents and physicians sometimes disregard adolescents' previously expressed wishes, particularly with regard to forgoing life-sustaining treatment. One of the goals of this intervention is to increase the congruence in treatment preferences between Spanish speaking adolescents with cancer and their families. Investigators also hope to resolve potential conflict about these decisions within the structure of the intervention through referrals to the ethics committee and chaplaincy program. One way the proposed FACE-TC Sp intervention differs from the SUPPORT study is that investigators include both the patient and surrogate in the decision-making process by actively engaging interested adolescents and families in facilitated conversations by a highly trained/certified interviewer about the end-of-life preferences that adolescents have.
Only three pediatric ACP (pACP) programs are reported in the peer reviewed literature.1 A qualitative study, FOOTPRINTS™, focused on patients aged 8-20 years with Duchennes' Muscular Dystrophy. The second involved conversations between an ethicist and parents of children who were dying about the parent's goals for their child's care. Voicing My CHOICES™ is a model currently being tested with young adults by Wiener and colleagues. Investigators are exploring whether completion of an ACP document, by seriously ill young adults will foster future discussions with family and the physician regarding the young adult's personal goals, values or beliefs. Only Lyon's (PI) pilot study of FAmily CEntered ACP for Teens with Cancer (FACE-TC) employed a randomized controlled trial (RCT) to evaluate a structured pACP intervention. Adolescents/family dyads were randomized to FACE-TC Sp or a Treatment as Usual condition. See Preliminary Studies. In a systematic review of children's engagement in health related decisions, only the FACE pilot focused on children's participation in decisions about their medical care with their family. The FACE pACP approach offers the following advantages over other previous approaches. It is family-centered and disease-specific. It integrates the Representational Approach to Patient Education, which focuses first on assisting individuals to understand their medical condition, to explore values and goals, and to begin weighing the benefits and burdens of any life-sustaining treatment compared to personal/family values and goals. It is delivered by trained/certified facilitators. It focuses on promoting psychological well-being in the face of serious illness, consistent with the recommendations of Folkman. This inclusion of families is a core value of Spanish speaking families, as is religion. A majority of Hispanic adults (55%) say they are Catholic, while 16% are evangelical Protestants and 5% are mainline Protestants.
The adaptation and pilot test of FACE-TC Sp will advance scientific knowledge by contributing to understanding what Hispanic/Latino adolescents living with cancer want with respect to goals of care and treatment preferences in the context of family support and enable us to put into practice recommended policies and understand how culture and spiritual experiences influence pACP outcomes.
- Conditions
- Cancer
- Being tested
- FACE-TC SP, Treatment as Usual
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FACE-TC SPBehavioural
The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
Treatment as UsualBehavioural
Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
| Study group | Role | What they receive |
|---|---|---|
| FACE-TC SP | Experimental | The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction. Receives: Behavioral: FACE-TC SP |
| Treatment As Usual | Active comparator | Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals. Receives: Behavioral: Treatment as Usual |
What is being measured
The primary outcome is the main question the study is designed to answer.
Development/Adaptation FACE TC for Spanish Speaking Teens
Adapting and tailoring this evidence-based intervention will be accomplished through well-established techniques. The community partner interviews will be achieved through our youth with cancer, families affected by cancer and community stakeholders. Logic modeling based on our previous research and a literature review is completed.
Study 1: Adolescent Focus Group: Do Hispanic/Latino Adolescents and Families Want to Be Involved in pediatric Advance Care Planning? We will conduct a 60 minute audio-taped focus group with five teens with cancer, ages 14-17, regarding what they would want and need when it comes to EOL care, as we have with our previous adaptations/development.11,59 We will review the English speaking version of the FACE protocol for changes (e.g. number of sessions, Five Wishes vs. Voicing My Choices).
Measured: 6 months
Lyon Advance Care Planning Survey-Adolescent & Family Versions
With the assistance of Children's National's Language Services (See Letter of Support) and our Hispanic chaplain and research staff we will translate and back translate the Lyon Advance Care Planning Survey-Adolescent and Surrogate version. We will then meet with adolescents with cancer and families to adapt/revise the survey (e.g. number of questions, best way to ask question, reading level).
Measured: 6 months
Family Focus Group with Hispanic/Latino Families about Program Development
Hispanic/Latino family members will be drawn from the Children's National Patient and Family Advisory Council (PFAC). We will conduct a 60 minute audio-taped focus group with Spanish speaking members. How should FACE-TC be adapted so as to be respectful of linguistic and cultural differences?
Measured: 6 months
Critical Review of Revised Protocol
Our community partners will meet in a Science Café to review the revised/adapted FACE-TC SP protocol. Rev. Roque will introduce the issues and the adapted study. We will explore thoughts, feelings and reactions until no new themes emerge and consensus is achieved.
Measured: 6 months
Secondary outcomes (1)
Pilot Test FACE-TC Spanish (FACE-TC Sp)
We are proposing to 1) study the feasibility, acceptability and safety of FACE-TC Sp; and 2) assess the effect of FACE-TC Sp on the primary (congruence in treatment preferences \& quality of communication) and secondary outcomes (quality of life \& plans and actions). We expect the FACE-TC Sp protocol will offer advantages over the existing standards, where adolescents 18 years of age or over are handed an advance directive form in the emergency department by a clerk or nurse, or otherwise mailed a form on their 18th birthday.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2019
- Study start12 Sep 2019
- Primary completion5 Aug 2021
- Study completion5 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This pilot will use a randomized control trial (RCT) design with the intent to treat. Randomization will be generated by computer to ensure the same numbers will be recruited to the FACE-TC Sp intervention and Treatment As Usual comparison group without bias, using a 1:1 ratio. We estimate that 32 adolescents ever diagnosed with cancer, aged 14 to 21, and 32 guardians/surrogates (N=64) will be enrolled and receive secondary screening. They will complete a Demographic Data Sheet. The assent/consent process focuses on readiness to participate, potential barriers to participation, as well as enhancing motivation. Adolescents and families will then be screened for eligibility. Eligible dyads, estimated to be 30 dyads, will complete baseline data. Then, the adolescent/family dyad will be randomly assigned to one of two conditions: 15 dyads will be assigned to FACE-TC SP and 15 dyads to Treatment As Usual.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Maureen Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Maureen Lyon, Children's National Research Institute
- Investigators
- Maureen E Lyon, PhD, Principal investigator, Center for Translational Research/Children's Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04095000
- Sponsor's protocol ID
- IRB 11473
- Acronym
- FACE-TC-Sp
- Status last verified
- Aug 2021
- First submitted
- 17 Sep 2019
- Last updated
- 9 Aug 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual patient data will not be shared. Deidentified data will be shared by contacting the PI upon completion of the study for appropriate research services.
Publications
Lyon ME, Arem H, Jacobs S. Health disparities: Barriers to building effective palliative end-of-life care for Spanish speaking teens with cancer. Clinical Practice in Pediatric Psychology. CPP-2020-0439R1. In press.
Study at a glance
From the registry record, last updated by the sponsor on 9 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Health Equity: Advance Care Planning for Spanish Speaking Teens With Cancer-1st Resubmission
- ClinicalTrials.gov ID
- NCT04095000
- Acronym / sponsor ID
- FACE-TC-Sp / IRB 11473
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Maureen LyonUniversity, hospital or other
- Study start
- 12 Sep 2019 (actual)
- Primary completion
- 5 Aug 2021 (actual)
- Study completion
- 5 Aug 2021 (actual)
- First posted
- 19 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pediatric ACP (Advance Care Planning) (pACP) (1) Supports communication with children/adolescents at any stage of a serious illness in understanding their illness, complications, fears, and hopes, as well as treatment preferences regarding future medical care with their family; (2) Communicates these goals of care and treatment preferences with their physician; and (3) Documents these goals of care and end-of-life treatment preferences. Among adolescents, cancer is the leading cause of disease-related deaths. Survival has improved far less for 15 to 24 year-olds than it has for older patients. About one-fourth will die prematurely. No pediatric Advance Care Planning (pACP) model exists to serve Spanish speaking adolescents with cancer.
Objective: To take first steps to implement pACP as a routine, structured intervention in pediatric hospitals with underserved Spanish speaking adolescents living with cancer through timely conversations with their families to relieve suffering (physical, psychological, spiritual) and maximize the quality of life
Detailed description
Non-English-speaking patients are far less likely to have advance care planning documents than English speakers. Some ethnicities in an adult study had no patients with an advance care planning document. Since completing advance care planning may increase early palliative care enrollment, as it did in the FACE-TC study, strategies to promote pACP are urgently needed, particularly with non-English speaking patients.
Transactional stress and coping theory is the basis for the FACE intervention, because interventions can change the appraisal of an illness from that of a death threat to a challenge with potential for personal growth and mastery.
Many adolescents want to talk about their goals and values regarding their own end-of-life care. These important discussions are often regarded as needed, but not initiated before a medical crisis, due to perceived (and unwarranted) fears they will cause anxiety, take away hope or cause physician or family discomfort. Parents who discussed death with their children who were dying of cancer reported no regrets. Pediatric ACP for adolescent cancer patients is a public health issue, because of its high burden and potential for the prevention of suffering, as most teen and young adult cancer patients at end of life get aggressive care. The proposed study will explore prospectively whether Hispanic/Latino teens can be safely supported to help them make informed choices with their families, advancing clinical practice. Heretofore, family refers to the legal guardian(s) or surrogate decision maker(s) of the adolescent patient with cancer.
Age appropriate communication that includes the adolescent and family can facilitate decisions about medical treatments that precede death. Competency to participate in decision-making has been challenged by research on adolescent brain development, which demonstrates the structure of the adolescent brain is not fully formed.
However, what these findings mean in terms of the actual functioning or behavior of an individual adolescent is unclear, stirring up legal and public policy debates. The implications for pACP are unclear. Empirical evidence and the ethical principles of justice and autonomy support the practice of including adolescents in decision-making about their future medical care, if they could not speak for themselves. Cognitive capacities required for "informed consent" for medical treatment exist in early adolescence. Nor is there reason to suspect that young adolescents have a less mature understanding of death: irreversibility; finality or non-functionality; universality or inevitability; and causality. Hinds and colleagues found that children with cancer realized they were involved in an end-of-life decision, understood the consequences of their decision (that death is the outcome no matter what), and could share the reasons for their preferences. The decision factors most frequently reported by pediatric patients were relationship based, while parents identified good communication. Parents also thought that communicating with the child about end-of-life preferences was appropriate when approached with sensitivity and care. The issues facing adolescents with a life-threatening illness are different from those facing adults, because minors' preferences are not legally binding.
Culture and ethnicity are important in pACP. Cultural values differ with respect to patient autonomy. For those adolescents who do not want to defer these decisions to their family or physician, culturally sensitive pACP conversations may ensure patients and families feel cared for and supported, when there is full participation by the family and clear communication to the physician. Hospice surveys show one-third of Latinos opposed life support that prolonged suffering, leading the National Hospice and Palliative Care Organization to actively reach out to Latino communities. Immigrant status influences decisions about aggressive treatments, suggesting there may not be disparities in EOL care, but rather differences in preferences. Investigators will explore whether the number of years residing in the U.S. influences treatment choices among study participants.
The FACE intervention is informed by the American Academy of Pediatrics, the Institute of Medicine (IOM), institutional guidelines, and evolving practice and theory recommending: (1) that decisions about end-of-life (EOL) care be shared among the adolescent patient, family, and physician; (2) that these discussions take place when the patient is stable; (3) and that decisions be individualized. In the SUPPORT study physicians misunderstood the patient's preferences about CPR in 80% of the cases. Clinical reports suggest that parents and physicians sometimes disregard adolescents' previously expressed wishes, particularly with regard to forgoing life-sustaining treatment. One of the goals of this intervention is to increase the congruence in treatment preferences between Spanish speaking adolescents with cancer and their families. Investigators also hope to resolve potential conflict about these decisions within the structure of the intervention through referrals to the ethics committee and chaplaincy program. One way the proposed FACE-TC Sp intervention differs from the SUPPORT study is that investigators include both the patient and surrogate in the decision-making process by actively engaging interested adolescents and families in facilitated conversations by a highly trained/certified interviewer about the end-of-life preferences that adolescents have.
Only three pediatric ACP (pACP) programs are reported in the peer reviewed literature.1 A qualitative study, FOOTPRINTS™, focused on patients aged 8-20 years with Duchennes' Muscular Dystrophy. The second involved conversations between an ethicist and parents of children who were dying about the parent's goals for their child's care. Voicing My CHOICES™ is a model currently being tested with young adults by Wiener and colleagues. Investigators are exploring whether completion of an ACP document, by seriously ill young adults will foster future discussions with family and the physician regarding the young adult's personal goals, values or beliefs. Only Lyon's (PI) pilot study of FAmily CEntered ACP for Teens with Cancer (FACE-TC) employed a randomized controlled trial (RCT) to evaluate a structured pACP intervention. Adolescents/family dyads were randomized to FACE-TC Sp or a Treatment as Usual condition. See Preliminary Studies. In a systematic review of children's engagement in health related decisions, only the FACE pilot focused on children's participation in decisions about their medical care with their family. The FACE pACP approach offers the following advantages over other previous approaches. It is family-centered and disease-specific. It integrates the Representational Approach to Patient Education, which focuses first on assisting individuals to understand their medical condition, to explore values and goals, and to begin weighing the benefits and burdens of any life-sustaining treatment compared to personal/family values and goals. It is delivered by trained/certified facilitators. It focuses on promoting psychological well-being in the face of serious illness, consistent with the recommendations of Folkman. This inclusion of families is a core value of Spanish speaking families, as is religion. A majority of Hispanic adults (55%) say they are Catholic, while 16% are evangelical Protestants and 5% are mainline Protestants.
The adaptation and pilot test of FACE-TC Sp will advance scientific knowledge by contributing to understanding what Hispanic/Latino adolescents living with cancer want with respect to goals of care and treatment preferences in the context of family support and enable us to put into practice recommended policies and understand how culture and spiritual experiences influence pACP outcomes.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- This pilot will use a randomized control trial (RCT) design with the intent to treat. Randomization will be generated by computer to ensure the same numbers will be recruited to the FACE-TC Sp intervention and Treatment As Usual comparison group without bias, using a 1:1 ratio. We estimate that 32 adolescents ever diagnosed with cancer, aged 14 to 21, and 32 guardians/surrogates (N=64) will be enrolled and receive secondary screening. They will complete a Demographic Data Sheet. The assent/consent process focuses on readiness to participate, potential barriers to participation, as well as enhancing motivation. Adolescents and families will then be screened for eligibility. Eligible dyads, estimated to be 30 dyads, will complete baseline data. Then, the adolescent/family dyad will be randomly assigned to one of two conditions: 15 dyads will be assigned to FACE-TC SP and 15 dyads to Treatment As Usual.
| Arm | Type | Receives |
|---|---|---|
| FACE-TC SP | Experimental | Behavioral: FACE-TC SPThe current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction. |
| Treatment As Usual | Active comparator | Behavioral: Treatment as UsualTreatment as Usual comparison condition will also be assessed and measures administered at the same time intervals. |
Who may qualify
- Ages
- 14 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FACE-TC SPThe current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction. | Behavioural | FACE-TC SP |
| Treatment as UsualTreatment as Usual comparison condition will also be assessed and measures administered at the same time intervals. | Behavioural | Treatment As Usual |
Primary outcome
Development/Adaptation FACE TC for Spanish Speaking Teens
Time frame: 6 months
Adapting and tailoring this evidence-based intervention will be accomplished through well-established techniques. The community partner interviews will be achieved through our youth with cancer, families affected by cancer and community stakeholders. Logic modeling based on our previous research and a literature review is completed. Study 1: Adolescent Focus Group: Do Hispanic/Latino Adolescents and Families Want to Be Involved in pediatric Advance Care Planning? We will conduct a 60 minute audio-taped focus group with five teens with cancer, ages 14-17, regarding what they would want and need when it comes to EOL care, as we have with our previous adaptations/development.11,59 We will review the English speaking version of the FACE protocol for changes (e.g. number of sessions, Five Wishes vs. Voicing My Choices).
Lyon Advance Care Planning Survey-Adolescent & Family Versions
Time frame: 6 months
With the assistance of Children's National's Language Services (See Letter of Support) and our Hispanic chaplain and research staff we will translate and back translate the Lyon Advance Care Planning Survey-Adolescent and Surrogate version. We will then meet with adolescents with cancer and families to adapt/revise the survey (e.g. number of questions, best way to ask question, reading level).
Family Focus Group with Hispanic/Latino Families about Program Development
Time frame: 6 months
Hispanic/Latino family members will be drawn from the Children's National Patient and Family Advisory Council (PFAC). We will conduct a 60 minute audio-taped focus group with Spanish speaking members. How should FACE-TC be adapted so as to be respectful of linguistic and cultural differences?
Critical Review of Revised Protocol
Time frame: 6 months
Our community partners will meet in a Science Café to review the revised/adapted FACE-TC SP protocol. Rev. Roque will introduce the issues and the adapted study. We will explore thoughts, feelings and reactions until no new themes emerge and consensus is achieved.
1 secondary outcome
Pilot Test FACE-TC Spanish (FACE-TC Sp)
Time frame: 24 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Aug 2021.
- Results publicationLyon ME, Arem H, Jacobs S. Health disparities: Barriers to building effective palliative end-of-life care for Spanish speaking teens with cancer. Clinical Practice in Pediatric Psychology. CPP-2020-0439R1. In press.
- Individual participant dataSharing planned: No. Individual patient data will not be shared. Deidentified data will be shared by contacting the PI upon completion of the study for appropriate research services.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maureen E Lyon, PhD principal investigator
Center for Translational Research/Children's Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing FACE-TC SP and Treatment as Usual in people with Cancer, run by Maureen Lyon at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Development/Adaptation FACE TC for Spanish Speaking Teens (time frame: 6 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04095000, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2021; AzTrials last refreshed its copy on 8 Nov 2026.